CLASS ACTION UPDATE for ITRM, SLQT and SPPI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
*NEW YORK, NY / ACCESSWIRE / September 17, 2021 /* Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
*ITRM Shareholders Click Here: *https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19654&wire=1
*SLQT Shareholders Click Here: *https://www.zlk.com/pslra-1/selectquote-inc-loss-submission-form?prid=19654&wire=1
*SPPI Shareholders Click Here: *https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19654&wire=1
** ADDITIONAL INFORMATION BELOW **
*Iterum Therapeutics Plc (NASDAQ:ITRM)*
*ITRM Lawsuit on behalf of:* investors who purchased November 30, 2020 - July 23, 2021
*Lead Plaintiff Deadline*: October 4, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19654&wire=1
According to the filed complaint, during the class period, Iterum Therapeutics Plc made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
*Selectquote, Inc. (NYSE:SLQT)*
*SLQT Lawsuit on behalf of:* investors who purchased February 8, 2021 - May 11, 2021
*Lead Plaintiff Deadline*: October 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/selectquote-inc-loss-submission-form?prid=19654&wire=1
According to the filed complaint, during the class period, Selectquote, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
*Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)*
*SPPI Lawsuit on behalf of:* investors who purchased December 27, 2018 - August 5, 2021
*Lead Plaintiff Deadline*: November 1, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19654&wire=1
According to the filed complaint, during the class period, Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
*You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff.* Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
*CONTACT:*
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
*SOURCE: *Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/664529/CLASS-ACTION-UPDATE-for-ITRM-SLQT-and-SPPI-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders